A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease

被引:0
|
作者
Rugeri, Lucia [1 ]
Thomas, Will
Schirner, Kathrin
Heyder, Lisa
Auerswald, Guenter
机构
[1] Hop Cardiol, Unite Hemostase Clin, Hosp Civils Lyon, Lyon, France
关键词
blood products; factor VIII; systematic review; von Willebrand disease; von Willebrand factor; WFH; 2021; GUIDELINES; INHIBITOR DEVELOPMENT; VENOUS THROMBOSIS; CLINICAL-EFFICACY; MANAGEMENT; BIOSTATE(R); DIAGNOSIS; PHARMACOKINETICS; POPULATION; PREVENTION;
D O I
10.1055/a-2253-9701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background For the treatment of von Willebrand disease (VWD), von Willebrand factor (VWF) concentrates can be used in on-demand, long-term prophylaxis, and surgical prophylaxis regimens. Methods This systematic literature review was conducted to evaluate the efficacy, consumption, and safety of plasma-derived human coagulation FVIII/human VWF (pdVWF/FVIII; Voncento/Biostate) for the treatment of patients with any inherited VWD type. An electronic search was conducted in MEDLINE and Cochrane Library databases on VWD therapies. All retrieved publications were assessed against predefined inclusion/exclusion criteria following the Cochrane group recommendations. Associated pharmacovigilance data were collected across the same time period. Results Eleven publications from eight study cohorts were identified for data retrieval. All were from multicenter studies and included both pediatric and adult patients. Eight publications included evaluations of the efficacy of pdVWF/FVIII for on-demand treatment, eight included long-term prophylactic treatment, and eight included surgical prophylaxis. Treatment protocols and VWF administration methods differed between studies, as did safety evaluations. The clinical response was rated as excellent/good for on-demand treatment in 66 to 100% of nonsurgical bleeds, 89 to 100% in the treatment of breakthrough bleeds during long-term prophylaxis treatment, and hemostatic efficacy in surgical procedures was 75 to 100%. Pharmacovigilance data confirmed a low incidence of adverse events in treated patients. Conclusion This review provides a comprehensive summary of studies that evaluated the use of pdVWF/FVIII in VWD demonstrating the long-term effectiveness and safety of this pdVWF/FVIII across all ages, types of VWD, and treatment settings.
引用
收藏
页码:828 / 841
页数:14
相关论文
共 50 条
  • [31] TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN PAEDIATRIC PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS
    Goudemand, J.
    Borel-Derlon, A.
    Henriet, C.
    Repesse, Y.
    Susen, S.
    HAEMOPHILIA, 2023, 29 : 147 - 147
  • [32] TREATMENT WITH A PLASMA-DERIVED VON WILLEBRAND FACTOR (VWF) ALMOST DEVOID OF FACTOR VIII IN ELDERLY PATIENTS WITH VON WILLEBRAND DISEASE (VWD): A POOLED ANALYSIS
    Goudemand, J.
    Derlon, A. Borel
    Henriet, C.
    Susen, S.
    Repesse, Y.
    HAEMOPHILIA, 2022, 28 : 109 - 110
  • [33] Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease
    Batlle, Javier
    Fernanda Lopez-Fernandez, Maria
    Loures Fraga, Esther
    Rodriguez Trillo, Angela
    Almudena Perez-Rodriguez, Maria
    BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (02) : 89 - 100
  • [34] A RETROSPECTIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A PLASMA-DERIVED, VON WILLEBRAND FACTOR-CONTAINING FVIII CONCENTRATE, IN PATIENTS WITH VON WILLEBRAND DISEASE IN SPAIN: STUDY DESIGN AND PROGRESS
    Jimenez-Yuste, V.
    Mir, R.
    HAEMOPHILIA, 2020, 26 : 141 - 141
  • [35] An open-label, multi-center extension study to assess the efficacy and safety of a plasma-derived von willebrand factor/factor VIII (VWF/FVIII) concentrate in pediatric, adolescent, and adult subjects with von willebrand disease
    Lissitchkov, T.
    Klukowska, A.
    Kuliczkowski, K.
    Buevich, E.
    Auerswald, G.
    Stasyshyn, O.
    Seifert, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 495 - 496
  • [36] Efficacy of factor VIII/von Willebrand factor concentrate Alphanate® in preventing excessive bleeding during surgery in subjects with von Willebrand disease
    Rivard, G. E.
    Aledort, L.
    HAEMOPHILIA, 2008, 14 (02) : 271 - 275
  • [37] Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience
    Batty, P.
    Chen, Y. -H.
    Bowles, L.
    Hart, D. P.
    Platton, S.
    Pasi, K. J.
    HAEMOPHILIA, 2014, 20 (06) : 846 - 853
  • [38] Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience
    Batty, P.
    Chen, Y. H.
    Platton, S. J.
    Bowles, L.
    Hart, D. P.
    Pasi, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 548 - 548
  • [39] Efficacy and safety of a von Willebrand factor concentrate with a low FVIII content in children with von Willebrand disease (vwd)
    Borel-Derlon, A.
    Aronis, S.
    Platokouki, H.
    Maes, P.
    Chatelanaz, C.
    Bridey, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 530 - 530
  • [40] Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE® in patients with von Willebrand's disease: a prospective multi-centre study
    Dunkley, S.
    Baker, R. I.
    Pidcock, M.
    Price, J.
    Seldon, M.
    Smith, M.
    Street, A.
    Maher, D.
    Barrese, G.
    Stone, C.
    Lloyd, J.
    HAEMOPHILIA, 2010, 16 (04) : 615 - 624